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Purpose/Objective: To derive a reference, based on portal imaging 
acquisitions, to ensure the constance and stability of FFF beams using 
the parameters defined in Med. Phys. (39), 2012.  
Materials and Methods: On Varian TrueBeam linac, the PV-aS1000 
detector response was investigated for 6 and 10 MV FFF beams. With 
an adequate source to detector distance, e.g. SDD=150 cm, even with 
the maximum dose rate of 1400 and 2400 MU/min the integrated 
image does not present saturation. This allows its usage for dosimetric 
evaluations also for FFF beams. Feasibility tests were performed on 
four different TrueBeam machines (two equipped with a high-
definition MLC, HD-120MLC, and two with a standard Millenium 120-
MLC) for a predefined set of beam settings. Comparisons with 
calculations in the Eclipse treatment planning system with AAA 
(Anisotropic Analytical Algorithm) were also carried out. Different 
open square and rectangular fields were periodically acquired for 6 
and 10 MV FFF beams at SDD=150 cm for the maximum available dose 
rate, as well as at SDD=100 cm using a lower dose rate (800 MU/min), 
over a period of six months. Integrated images were converted into 
absorbed dose to water through the GLAaS algorithm [Med Phys (33), 
2006], adapted to FFF beams. Data were analysed and different 
parameters were recorded: dose on the beam central axis, profile 
parameters as unflatness,slope, peak position and symmetry. Similar 
analysis was also derived from measurements acquired with 2-D ion 
chamber array, StarCheck (PTW), and used as benchmark. 
Results: Dose profile percentage differences within the 80% of the 
field size, between measurements and AAA calculations, resulted in -
0.5±0.8% and -0.8±0.7% for 6 and 10 MV FFF, respectively. Similar 
deviation values were recorded for unflatness, symmetry and peak 
position. Constancy of repeated periodic portal image acquisition 
converted into dose resulted in the following values: output factors 
variation -0.13±0.17%, dose difference in the field region (80% of the 
field size): 0.15±0.26%. The gamma evaluation was conducted with 
two sets of distance-to-agreement and dose difference criteria of 
2mm/2% and 1mm/2%. The corresponding percentage of point passing 
the gamma evaluation were 99.7±0.6% and 99.3±1.6%, respectively for 
the two criteria. 
Conclusions: The possibility to effectively use the Portal Vision for 
open field quality assurance of FFF beams was assured. Constancy and 
stability evaluated with the profile parameters were consistent with 
other measurements or calculations. This fact allows to set-up fast 
and safe linac quality assurance procedures also for FFF beams.  
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Purpose/Objective: The aim of this work is to investigate the 
predictive power of the Gamma passing rate (%GP) IMRT QA metric in 
order to evaluate whether the standard action levels used by most 
clinics are justified. Sensitivity and specificity analysis between %GP 
and different dose discrepancy between planned and perturbed DVH is 
performed. The perturbed DVH is calculated by using a dedicated 
software, 3DVH (Sun Nuclear Corporation), which is able to modify the 
dose distribution calculated by the Treatment Planning System (TPS) 
according to the dose discrepancies detected with pre-treatment 
measurements. Sensitivity was calculated to correctly identify the 
pre-treatment plans with high dose errors, varying the Gamma 
Index(GI) criteria and the preselected thresholds. Also specificity was 
calculated. 
Materials and Methods: 27 prostate cancer patients and 15 head and 
neck cancer patients, treated with IMRT-sliding window technique, 
were analyzed. Pre-treatment verifications were performed for all 
patients’ plans by acquiring plane dose distributions of each 
treatment field with the diode array MapCheck (Sun Nuclear 
Corporation). Measured and calculated dose distributions were 
compared using the global and local GI method, and %GP were 
generated using the following acceptance criteria: 1%/1mm, 2%/2 
mm, and 3%/3 mm. Planar measured dose distributions, together with 
patient's DICOM RT Plan, Structure and Dose files from TPS were 
loaded into the 3DVH software. Percentage dose differences between 
DVHs, obtained by TPS and by 3DVH were calculated. A value of %GP 
of 95% and the mean absolute DVH dose error 3% and 5% were used as 
thresholds to calculate sensitivity and specificity. 
Results: The results are reported in the Table 1. We found an 
excellent sensitivity (>0.93) for global and local methods with 
2%/2mm and a good sensitivity (>0.80) with 3%/3mm for local 
normalization. Instead we obtained a poor sensitivity (<0.4) with 
3%/3mm for global normalization. Our results confirmed that in 
general the local normalization method is more sensitive than global. 
Obtained 3%/3mm specificity was always higher than 2%/2mm 
criterion and,in particular, for the threshold of %GP> 95%with a 
2%/2mm criterion, the specificity value was very low (<0.2). So, in 
this case, even if the sensitivity is excellent, is not applicable in 
clinical routine because in our experience only 11% of plans pass this 
threshold. To have a higher value of specificity (>0.6) and good 
sensitivity (0.9) is necessary to use a threshold of %GP>90% for 
2%/2mm criterion. 
  
Conclusions: The low sensitivity of 3%/3mm global gamma method 
and 95% of %GP threshold show that the most common published 
acceptance criteria have disputable predictive power for pre-patient 
IMRT QA. The %GP, although it provides the quantity of errors, does 
not specify the magnitude of errors. Further investigations are 
strongly advised concerning the clinical relevance of GI analysis.  
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Purpose/Objective: To assess in-vivo the dose delivered to the target 
volume during volumetric modulated arc therapy (VMAT) in patients 
with anal or rectal cancer using thermoluminescent dosimeters (TLDs) 
whose anatomical position was evaluated using cone-beam computed 
tomography scans (CBCTs). 
Materials and Methods: A new procedure was used to perform in-vivo 
dosimetry using TLDs placed in rectal probes in high-dose regions. 
Using CBCT images and image fusion, TLDs were located respect to 
planned treatments, and expected dose estimated. We present the 
results of 10 patients treated with VMAT for ano-rectal cancer. Eclipse 
ver.10 was used for planning and patients were treated on a 2100C/D 
Varian linac equipped with on-board imaging. The prescribed dose to 
the gross tumor volume (GTV) was 1.8 Gy and 2 Gy for patients with 
anal (n=8) and rectal (n=2) cancer, respectively. The delivered dose to 
the elective clinical target volume for rectal cancer patients was 1.8 
Gy per fraction, using a simultaneous integrated boost technique. Five 
TLDs were fitted in a Rando phantom to evaluate TLDs readings 
contribution resulting from CBCT imaging. 
Results: TLDs reading in the Rando phantom, after irradiation with a 
standard pelvis CBCT protocol, resulted in 2 cGy dose contribution for 
all 5 TLDs, approximately 1% of the prescribed dose. These readings 
were neglected in the present analysis.  
A total of 52 measurements (43 and 9 for patients with anal and rectal 
cancer, respectively) were analyzed. Six TLDs were placed on the GTV 
located at anal verge in the perianal skin. Median planned and 
measured doses were 1.8 Gy (range, 1.09-2.02 Gy) and 1.81 Gy 
(range, 0.94-2.14 Gy), respectively. In percentage of the prescribed 
dose it corresponded to 100% (range, 60.6-106.7%) and 100.5% (range, 
52.2-112.2%) for planned and measured values, respectively. Overall, 
TLD doses measurements differed by a median dose of 0.035 Gy, 
ranging between -0.16 and 0.21 Gy (median difference in percentage 
of 1.9%, range –8.9%/+11.7%) in comparison to the planned doses. 
Differences ≤5% or ≥5% between calculated and estimated doses were 
